Dual targeting of the PI3K/Akt/mTOR pathway as an antitumor strategy in Waldenstrom macroglobulinemia.

@article{Roccaro2010DualTO,
  title={Dual targeting of the PI3K/Akt/mTOR pathway as an antitumor strategy in Waldenstrom macroglobulinemia.},
  author={Aldo M Roccaro and Antonio Sacco and Emanuel N Husu and Costas Pitsillides and Steven Vesole and Abdel Kareem Azab and Feda Azab and Molly M Melhem and Hai T. Ngo and Phong Quang and Patricia Maiso and Judith Runnels and M Liang and Kwok-kin Wong and Charles Lin and Irene M Ghobrial},
  journal={Blood},
  year={2010},
  volume={115 3},
  pages={559-69}
}
We have previously shown clinical activity of a mammalian target of rapamycin (mTOR) complex 1 inhibitor in Waldenstrom macroglobulinemia (WM). However, 50% of patients did not respond to therapy. We therefore examined mechanisms of activation of the phosphoinositide 3-kinase (PI3K)/Akt/mTOR in WM, and mechanisms of overcoming resistance to therapy. We first demonstrated that primary WM cells show constitutive activation of the PI3K/Akt pathway, supported by decreased expression of phosphate… CONTINUE READING
52 Citations
35 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 52 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 35 references

A phase II trial of the oral mTOR inhibitor everolimus (RAD001) in relapsed or refractory Waldenstrom’s macroglobulinemia

  • IM Ghobrial, M Gertz, B LaPlant
  • J Clin Oncol
  • 2009

Similar Papers

Loading similar papers…